采用乳液聚合方法将引发剂过硫酸铵(APS)和乳化剂十二烷基硫酸钠(SDS)制备出聚丙烯酸树脂乳液,再加入不同条件交联剂固化成聚丙烯酸(PAA)水凝胶,并探究使用紫外固化和热固化2种不同固化方式及不同固化时间对PAA水凝胶性能的影响。通过...采用乳液聚合方法将引发剂过硫酸铵(APS)和乳化剂十二烷基硫酸钠(SDS)制备出聚丙烯酸树脂乳液,再加入不同条件交联剂固化成聚丙烯酸(PAA)水凝胶,并探究使用紫外固化和热固化2种不同固化方式及不同固化时间对PAA水凝胶性能的影响。通过氮气等温吸脱附曲线测试(Brunauer-Emmet-Teller,BET)、扫描电子显微镜(scanning electron microscope,SEM)、热失重分析(thermogravimetric analysis,TGA)、溶胀度、力学测试等方法,对水凝胶的性能进行表征分析。结果表明,形成的PAA水凝胶主要为片状颗粒材料,在紫外固化20 min条件下,其孔径主要分布在2~4 nm;且在热固化条件下,当交联剂质量浓度为0.06、0.07 g/mL时PAA水凝胶溶胀度可达到667%,在交联剂质量浓度为0.09 g/mL时拉伸强度可达到60 k Pa。综上所述,对比紫外固化和热固化2种方法以及不同条件交联剂下制备的PAA水凝胶的差异,对理解和优化PAA水凝胶的制备具有一定的指导意义。展开更多
Dermalive, an injectable skin filler composed of a combination of synthetic hyaluronic acid and acrylic hydrogel particles was recently developed for soft tissue augmentation. Dermalive produces longer term results th...Dermalive, an injectable skin filler composed of a combination of synthetic hyaluronic acid and acrylic hydrogel particles was recently developed for soft tissue augmentation. Dermalive produces longer term results than temporary injectable fillers and is associated with a reportedly low incidence of adverse reactions. We describe a marked local reaction to the injection of Dermalive in the nasolabial fold developing within 4 months with histological confirmation of a granulomatous response. To our knowledge there has been only one previous report of alocal granulomatous reaction to Dermalive.展开更多
文摘采用乳液聚合方法将引发剂过硫酸铵(APS)和乳化剂十二烷基硫酸钠(SDS)制备出聚丙烯酸树脂乳液,再加入不同条件交联剂固化成聚丙烯酸(PAA)水凝胶,并探究使用紫外固化和热固化2种不同固化方式及不同固化时间对PAA水凝胶性能的影响。通过氮气等温吸脱附曲线测试(Brunauer-Emmet-Teller,BET)、扫描电子显微镜(scanning electron microscope,SEM)、热失重分析(thermogravimetric analysis,TGA)、溶胀度、力学测试等方法,对水凝胶的性能进行表征分析。结果表明,形成的PAA水凝胶主要为片状颗粒材料,在紫外固化20 min条件下,其孔径主要分布在2~4 nm;且在热固化条件下,当交联剂质量浓度为0.06、0.07 g/mL时PAA水凝胶溶胀度可达到667%,在交联剂质量浓度为0.09 g/mL时拉伸强度可达到60 k Pa。综上所述,对比紫外固化和热固化2种方法以及不同条件交联剂下制备的PAA水凝胶的差异,对理解和优化PAA水凝胶的制备具有一定的指导意义。
文摘Dermalive, an injectable skin filler composed of a combination of synthetic hyaluronic acid and acrylic hydrogel particles was recently developed for soft tissue augmentation. Dermalive produces longer term results than temporary injectable fillers and is associated with a reportedly low incidence of adverse reactions. We describe a marked local reaction to the injection of Dermalive in the nasolabial fold developing within 4 months with histological confirmation of a granulomatous response. To our knowledge there has been only one previous report of alocal granulomatous reaction to Dermalive.
